BIIB
渤健(BIIB.US)上调2025年全年业绩指引。
时间:2025-07-31 18:21:52 市场: 美股 综合
Truist证券将渤健公司(BIIB.US)评级从“买入”降至“持有”,目标价从199美元大幅下调至142美元。
时间:2025-07-21 19:27:34 市场: 美股 综合
Eisai: Update on Cost-Effectiveness Evaluation of Leqembi by Japan's Health Ministry Council
时间:2025-07-09 14:05:20 市场: 美股 综合
Eisai: Will Continue to Seek Fair Evaluation of Value That Leqembi Brings
时间:2025-07-09 14:05:20 市场: 美股 综合
Biogen Inc - Estimated Charge to Impact EPS by ($0.26) per Share for Q2 - SEC Filing
时间:2025-07-08 04:11:22 市场: 美股 综合
Biogen Inc - Expects $46 Mln Expense for Bought R&D in Q2 2025 - SEC Filing
时间:2025-07-08 04:11:22 市场: 综合 美股
Biogen Shares up 5.8%
时间:2025-07-01 23:24:39 市场: 美股 综合
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
时间:2025-06-30 19:30:12 市场: 美股 综合
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in Sma
时间:2025-06-27 22:00:38 市场: 综合 美股
Biogen - Safety Profile of Higher Dose Regimen of Nusinersen Is Broadly Consistent With Known Safety Profile of 12 Mg Spinraza
时间:2025-06-27 22:00:38 市场: 美股 综合